Recombinant Tissue Plasminogen Activator-conjugated Nanoparticles Effectively Targets Thrombolysis in a Rat Model of Middle Cerebral Artery Occlusion

• Published in: Current medical science Vol. 38; no. 3; pp. 427 - 435
• Main Authors: Deng, Jun, Mei, Heng, Shi, Wei, Pang, Zhi-qing, Zhang, Bo, Guo, Tao, Wang, Hua-fang, Jiang, Xin-guo, Hu, Yu
• Format: Journal Article
• Language: English
• Published: Wuhan Huazhong University of Science and Technology 01.06.2018; Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology,Wuhan 430022, China; Key Laboratory of Targeted Biotherapy of Ministry of Education, Wuhan 430022, China%Department of Pharmaceutics, School of Pharmacy, Fudan University, Shanghai 200032, China
• Subjects: Medicine; Medicine & Public Health; recombinant tissue plasminogen activator; thrombolysis; nanoparticles; drug delivery system
• ISSN: 2096-5230; 2523-899X; 1672-0733; 2523-899X
• DOI: 10.1007/s11596-018-1896-z

Summary The efficacy and safety of recombinant tissue plasminogen activator (rtPA) need to be improved due to its low bioavailability and requirement of large dose administration. The purpose of this study was to develop a fibrin-targeted nanoparticle (NP) drug delivery system for thrombosis combination therapy. We conjugated rtPA to poly(ethylene glycol)- poly(e-caprolactone) (PEG-PCL) nanoparticles (rtPA-NP) and investigated its physicochemical characteristics such as particle size, zeta potential, enzyme activity of conjugated rtPA and its storage stability at 4°C. The thrombolytic activity of rtPA-NP was evaluated in vitro and in vivo as well as the half-life of rtPA-NP, the properties to fibrin targeting and its influences on systemic hemostasis in vivo . The results showed that rtPA-NP equivalent to 10% of a typical dose of rtPA could dissolve fibrin clots and were demonstrated to have a neuroprotective effect after focal cerebral ischemia as evidenced by decreased infarct volume and improved neurological deficit ( P <0.001). RtPA-NP did not influence the in vivo hemostasis or coagulation system. The half-life of conjugated rtPA was shown to be approximately 18 times longer than that of free rtPA. These experiments suggested that rtPA-conjugated PEG-PCL nanoparticles might be a promising fibrin-targeted delivery system for a combination treatment of thrombosis.